The utility of treating patients with FMF and colchicine and/or anti-IL-1 resistance (or intolerance) with tumor necrosis factor (TNF), IL-6, and Janus kinase (JAK) blocking agents is variable and limited to isolated case reports and small series [14]. This evidence concerns the gene TNF and familial Mediterranean fever.